17. 10. 2017 | krebs:hilfe!
In the randomised, double-blind phase III trial PACIFIC, durvalumab has shown to improve PFS while upholding quality of life measures in locally advanced, unresectable NSCLC patients after concurrent chemoradiation.
16. 10. 2017 | krebs:hilfe!
New research showed that among small cell lung cancer (SCLC) patients, the efficacy of using nivolumab with or without (±) ipilimumab was enhanced among those with a high tumor mutation burden (TMB).
14. 10. 2017 | krebs:hilfe!
Changes in LDH above the upper limit of normal values at cycle 2 and in NLR ≥ 5 at 6 weeks predicts for disease progression at the first tumour response evaluation.
13. 10. 2017 | krebs:hilfe!
The role of immunotherapy for patients with uncommon EGFR mutations, ROS1 and C-MET who express PD-L1 is still unclear.
Immunotherapy has differential effects at different organ sites of metastases.
12. 10. 2017 | krebs:hilfe!
Low absolute neutrophil count (ANC), high absolute lymphocyte count (ALC), and high absolute eosinophil count (AEC) was associated with a better outcome of nivolumab treatment.
Interferon-Gamma (IFNG) production by T-cells play a critical role in anti-cancer immune responses.
There is a positive correlation between increasing cutpoints of PD-L1 expression and ORR and 1yr PFS, but little correlation with 1yr OS in treatment naive and pretreated patients.
The 1% cut-off value for PD-L1 might become a better predictive marker than the other cut-off values, and even minimal expression of PD-L1 protein may have a negative prognostic significance.
The expression of PD-L1 was up-regulated after neo-adjuvant chemotherapy when using 5%, 10%, 20% expression threshold.
Mit einer Anmeldung bei medonline haben Sie Zugriff auf Fortbildungen, Arzneimittelinfos, Produktfortbildungen und mehr. Registrieren Sie sich kostenlos auf medonline.